Explanipedia

Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma Open

Jessica Gates, F Haris, Francesca Cefaloni, Paniz Khooshemehri, Linda Green , et al. · 2025

Introduction Tezepelumab is an anti‐TSLP monoclonal antibody approved for the treatment of severe asthma. It has broad downstream anti‐T2 effects, offering the prospect of biological remission. Real‐world data on clinical remission rates w…

M22 Change in FeNO with dupilumab and tezepelumab in severe eosinophilic asthma Open

Jessica Gates, A Hearn, A-C Maynard-Paquette, L Green, L Thomson , et al. · 2023

Background The level of fractional exhaled nitric oxide (FeNO) correlates with exacerbation risk and lung function decline in asthma and is a well-recognised biomarker of airway IL-13. FeNO has been shown to significantly fall following in…

S66 Long-term effectiveness of benralizumab and remission of EGPA: two year results from guy’s EGPA cohort Open

A-C Maynard-Paquette, AM Nanzer, V Alam, L Green, Louise Thomson , et al. · 2023

Background Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare multi-system vasculitis which has shown to be responsive to the anti-IL5 biologic mepolizumab in the phase 3 MIRRA trial. The anti-IL5R biologic benralizumab leads …

P172 Assessing the clinical effectiveness of a secondary care asthma hot clinic following hospital attendance with acute asthma exacerbation Open

C Roxas, N Dul, L Thomson, J Lam, Mariana Fernandes , et al. · 2023

Background Current guidelines recommend patient follow-up after an Emergency Department (ED) visit with acute asthma exacerbation (AE). This is frequently not routinely carried out in either primary or secondary care due to limited resourc…

P42 Asthma treatment adherence checks: present and future Open

N Stewart-Kelcher, A Patel, S. M. Mahbubur Rahman, A Hearn, C Roxas , et al. · 2021

Introduction In spite of its importance in optimising clinical outcomes and determining whether an escalation in therapy is indicated (e.g. initiating a biologic agent), the difficulty in identifying suboptimal adherence to asthma therapy …

S85 Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment Open

AP Hearn, MS Mak, Irilda Budaj, Nishat Tasnim Qurashi, Olivia Snell , et al. · 2021

Background Eosinophil-rich mucus plugs are a recognised feature of asthma and are believed to contribute to airflow obstruction. However, little is known about the incidence of plugging in severe eosinophilic asthma (SEA) and the relations…

P203 Effectiveness of anti-IL4R therapy following Suboptimal Response to anti-IL5/5R therapy in severe eosinophilic asthma Open

TW Mason, AP Hearn, Gianmarco D’Ancona, M Fernandes, C Roxas , et al. · 2021

Introduction Dupilumab is an anti-IL4R monoclonal antibody (mAb) with proven efficacy in severe eosinophilic asthma (SEA). We previously reported that a suboptimal response to the eosinophil-targeting anti-IL5/5R mAbs mepolizumab and benra…

Real World Effectiveness of Anti-IL-5/5R Therapies Is Independent of Co-Eligibility for Anti-IgE Therapy Open

A Hearn, O.D. Hug, Z.A. Somani, J Kavanagh, G d’Ancona , et al. · 2021

The Adherence to Inhaled Corticosteroid Therapy of Patients Referred to a UK Tertiary Asthma Clinic Open

G d’Ancona, J Laver, N. Stewart-Kercher, Syed Masiur Rahman, Mariana Fernandes , et al. · 2021

Can Healthcare Professionals Demonstrate the Use of a Metered Dose Inhaler Satisfactorily? Open

G d’Ancona, Mathumie Sivakanthan, N. Biju, Hetal Dhruve, L. Green , et al. · 2021

Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy Open

A Hearn, Oliver D. Hug, Ziana A. Somani, Joanne Kavanagh, G d’Ancona , et al. · 2021

In a real-world setting, the clinical response to the anti-IL-5/5R mAbs mepolizumab and benralizumab in patients with severe eosinophilic asthma is independent of co-eligibility with the anti-IgE mAb omalizumabhttps://bit.ly/2NfAitP

Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma Open

Joanne Kavanagh, A Hearn, G d’Ancona, Jaideep Dhariwal, C Roxas , et al. · 2020

Mepolizumab and benralizumab are monoclonal antibodies (mAb) directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces exacerbation rate and maintenance oral corticosteroid (mOCS) requirements in severe eosinophilic ast…

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis Open

Alexandra M. Nanzer, Jaideep Dhariwal, Joanne Kavanagh, A Hearn, Mariana Fernandes , et al. · 2020

Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf.

Differential Effects of Unscheduled ICS Withdrawal Between Patients Receiving Benralizumab and Mepolizumab Open

G d’Ancona, J Kavanagh, C Roxas, L Green, Mariana Fernandes , et al. · 2020

Recovery of Adrenal Function After Secondary Iatrogenic Adrenal Failure in Severe Asthma Patients Open

Alexandra M. Nanzer, Aqib B. Chowdhury, Mariana Fernandes, L Thomson, C Roxas , et al. · 2020

Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy Open

Alexandra M. Nanzer, Aqib B. Chowdhury, Asma Raheem, C Roxas, Mariana Fernandes , et al. · 2020

Adrenal insufficiency is common in previously steroid-dependent asthma patients. Morning serum cortisol is a valid and important first line test which can indicate adrenal insufficiency and can guide who might need dynamic testing.h…

Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Open

G d’Ancona, Joanne Kavanagh, C Roxas, Linda Green, Mariana Fernandes , et al. · 2020

Introduction Inhaled corticosteroids (ICS) achieve disease control in the majority of asthmatic patients, although adherence to prescribed ICS is often poor. Patients with severe eosinophilic asthma may require treatment with oral corticos…

Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis Open

Brian D. Kent, G d’Ancona, Mariana Fernandes, Linda Green, C Roxas , et al. · 2020

Blockade of interleukin-5 with reslizumab appears to have significant oral corticosteroid sparing effects in patients with eosinophilic granulomatosis with polyangiitis and severe eosinophilic asthma http://bit.ly/2D2yYSK.

Cris Roxas YOU? Author Swipe